Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: complete response + cll patients + combination  Related to the article below (Last Update: 5/13/2008)

BioCryst Reports First Quarter 2008 Financial Results and Clinical ...
Earthtimes (press release), UK - May 8, 2008
This second CLL trial is a single-arm study evaluating single agent forodesine HCl as a treatment for patients with CLL; response rate is the primary ...BCRX
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Earthtimes, UK - Apr 22, 2008
Bendamustine was recently approved by the FDA for the treatment of patients with CLL based on the results of a pivotal phase III study, which showed that ...
Bendamustine Added to US Treatment Guidelines for Leukaemia, Lymphomas
DG News - Apr 24, 2008
Bendamustine was recently approved by the US Food and Drug Administration for the treatment of patients with CLL based on the results of a pivotal phase 3 ...
Roche Continues Solid Sales Growth in First Quarter of 2008 - Both ...
PharmaLive.com (press release), PA - Apr 17, 2008
Increasingly, doctors are switching patients to MabThera/Rituxan after an inadequate response to one TNF inhibitor. MabThera/Rituxan is currently in phase ...

In order to show you the most relevant results, we have omitted some entries very similar to the 4 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic … -
B Kennedy, A Rawstron, C Carter, M Ryan, K Speed, … - Blood, 2002 - bloodjournal.hematologylibrary.org
... agent use in B-cell chronic lymphocytic leukemia (CLL) with reported ... fludarabine
in patients with CLL refractory to ... one who had a complete response by National ...

… concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell … -
JC Byrd, BL Peterson, VA Morrison, K Park, R … - Blood, 2003 - ncbi.nlm.nih.gov
... regimen was 90% (47% complete response [CR], 43 ... 23 months, the median response duration
and ... fludarabine in previously untreated CLL patients demonstrates marked ...

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated … -
IW Flinn, JC Byrd, C Morrison, J Jamison, LF Diehl … - Blood, 2000 - bloodjournal.hematologylibrary.org
... low-grade lymphomas and chronic lymphocytic leukemia (CLL) are often ... responses in
the majority of patients. ... it a significant increase in complete response rate ...

… a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic … -
H Schulz, SK Klein, U Rehwald, M Reiser, A Hinke, … - Blood, 2002 - bloodjournal.hematologylibrary.org
... The overall response rate (complete remission [CR] and partial ... stage C). The median
duration of response was 75 ... feasible and effective in patients with B-CLL. ...

Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or … -
T Elter, P Borchmann, H Schulz, M Reiser, S Trelle … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... P, et al: Early prediction of outcome and response to alemtuzumab ... Campath-1H therapy
in 29 patients with refractory CLL: ?True? complete remission is ...

… may prolong progression-free survival and overall survival in patients with previously untreated … -
JC Byrd, K Rai, BL Peterson, FR Appelbaum, VA … - Blood, 2005 - bloodjournal.hematologylibrary.org
... In parallel with response outcome, patients ... proportion of true complete remission
can ... with relapsed refractory chronic lymphocytic leukemia (CLL) treated with ...

… versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic … -
BF Eichhorst, R Busch, G Hopfinger, R Pasold, M … - Blood, 2006 - bloodjournal.hematologylibrary.org
... than 66 years who predominantly had advanced CLL were randomly ... resulted in significantly
higher complete remission rate (24%) and overall response rate (94 ...

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a … -
MJ Keating, I Flinn, V Jain, JL Binet, P Hillmen, … - Blood, 2002 - bloodjournal.hematologylibrary.org
... Treatment took up to 16 weeks to complete in 2 patients (2%) who received ... Response. ...
NCIWG criteria, 6 additional patients (7%) had clearing of B-CLL from all ...

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma -
JD Hainsworth, S Litchy, HA Burris III, DC Scullin … - Journal of Clinical Oncology, 2002 - jco.ascopubs.org
... 73%, with a 20% complete remission rate. ... weekly have suggested higher response rates
in patients with previously treated chronic lymphocytic leukemia (CLL). ...

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 … -
MS Czuczman, AJ Grillo-Lopez, CA White, M Saleh, L … - Journal of Clinical Oncology, 1999 - jco.ascopubs.org
... bulky disease (Table 3). Combination Rituxan and CHOP therapy achieved at least
a partial response in all of the patients, and the complete response rate was ...

Source: Google Scholar

Complete response with oblimersen combination improves survival of CLL patients

ATLANTA - Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Patients who achieved a complete response with oblimersen have survived so well that a median survival time cannot yet be calculated, but it is estimated to exceed 49 months. Those who achieved complete response with chemotherapy alone had a median survival time of 35 months.

"In a relapsed population, that's excellent survival," says lead author Susan O'Brien, M.D., professor in M. D. Anderson's Department of Leukemia. "Survival is associated with achieving complete response."

The Phase III clinical trial compared a regimen of fludarabine and cyclophosphamide (F/C) with F/C plus oblimersen. Known commercially as Genasense(r), oblimersen blocks the Bcl-2 protein, which plays a critical role in progression of chronic lymphocytic leukemia (CLL), including development of resistance to treatment.

By stifling Bcl-2, researchers believe CLL becomes more vulnerable to chemotherapy such as the F/C combination.

In a paper published in the Journal of Clinical Oncology in March, O'Brien and colleagues showed that patients who received the oblimersen combination were more likely to have a complete response (20 out of 120 patients, or 17 percent, compared to 8 out of 121 patients, 7 percent, who received only the F/C chemotherapy).

Complete response was more durable in the oblimersen-treated patients, with a median duration of at least 36 months compared with 22 months for those on F/C alone.

The question unanswered by the JCO paper was whether this advantage in complete response translated into an advantage in survival, O'Brien says.

Patients were followed for at least three years after randomization or until death or withdrawal from the study. Of the 20 oblimersen-treated patients with a complete response at the end of the first year, 12 survived at least four years. Of the eight complete responders in the other group, four survived at least four years.

The survival data confirm that complete response is a valid endpoint for clinical trials in relapsed or resistant CLL, O'Brien says.

###

Approval of Genasense(r), produced by Genta, Inc., for CLL is on appeal at the U.S. Food and Drug Administration.

Co-authors with O'Brien are: Joseph Moore, M.D., of Duke University Medical Center; Lily Ding, Ph.D., and Steven Novick, of Genta Inc.; and Kanti Rai, M.D., of Long Island Jewish Medical Center.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.